Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Robertson

Showing results (821-830 of 846) with videos related to

Pageof 85
Sort By:
Advanced Materials (Deerfield Beach, Fla.)|May 13, 2022
Achieving Ultrahigh-Rate Planar and Dendrite-Free Zinc Electroplating for Aqueous Zinc Battery AnodesShengda D Pu, Chen Gong, Yuanbo T Tang, et al.
Journal of Medicinal Chemistry|April 14, 2009
8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonistsPaul J Gilligan, Liqi He, Todd Clarke, et al.
Chest|November 7, 2022
Consensus Statements on Deployment-Related Respiratory Disease, Inclusive of Constrictive Bronchiolitis: A Modified Delphi StudyMichael J Falvo, Anays M Sotolongo, John J Osterholzer, et al.
The Journal of Biological Chemistry|August 1, 2000
Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitorsD Seiffert, J D Bradley, C M Rominger, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 27, 2004
Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in ratsSnjezana Lelas, Harvey Wong, Yu-Wen Li, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 9, 2020
Concanamycin A counteracts HIV-1 Nef to enhance immune clearance of infected primary cells by cytotoxic T lymphocytesMark M Painter, Gretchen E Zimmerman, Madeline S Merlino, et al.
Human Molecular Genetics|June 15, 2001
BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeuticsS L Roberds, J Anderson, G Basi, et al.
Biorxiv : the Preprint Server for Biology|September 30, 2024
The Pattern and Staging of Brain Atrophy in Spinocerebellar Ataxia Type 2 (SCA2): MRI Volumetrics from ENIGMA-AtaxiaJason W Robertson, Isaac Adanyeguh, Benjamin Bender, et al.
Environmental Health Perspectives|June 22, 2010
Research recommendations for selected IARC-classified agentsElizabeth M Ward, Paul A Schulte, Kurt Straif, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 10, 2025
The Pattern and Stages of Atrophy in Spinocerebellar Ataxia Type 2: Volumetrics from ENIGMA-AtaxiaJason W Robertson, Isaac Adanyeguh, Benjamin Bender, et al.
Pageof 85

Showing results (821-830 of 846) with videos related to

Sort By:
Pageof 85
Advanced Materials (Deerfield Beach, Fla.)|May 13, 2022
Achieving Ultrahigh-Rate Planar and Dendrite-Free Zinc Electroplating for Aqueous Zinc Battery AnodesShengda D Pu, Chen Gong, Yuanbo T Tang, et al.
Journal of Medicinal Chemistry|April 14, 2009
8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonistsPaul J Gilligan, Liqi He, Todd Clarke, et al.
Chest|November 7, 2022
Consensus Statements on Deployment-Related Respiratory Disease, Inclusive of Constrictive Bronchiolitis: A Modified Delphi StudyMichael J Falvo, Anays M Sotolongo, John J Osterholzer, et al.
The Journal of Biological Chemistry|August 1, 2000
Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitorsD Seiffert, J D Bradley, C M Rominger, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 27, 2004
Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in ratsSnjezana Lelas, Harvey Wong, Yu-Wen Li, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 9, 2020
Concanamycin A counteracts HIV-1 Nef to enhance immune clearance of infected primary cells by cytotoxic T lymphocytesMark M Painter, Gretchen E Zimmerman, Madeline S Merlino, et al.
Human Molecular Genetics|June 15, 2001
BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeuticsS L Roberds, J Anderson, G Basi, et al.
Biorxiv : the Preprint Server for Biology|September 30, 2024
The Pattern and Staging of Brain Atrophy in Spinocerebellar Ataxia Type 2 (SCA2): MRI Volumetrics from ENIGMA-AtaxiaJason W Robertson, Isaac Adanyeguh, Benjamin Bender, et al.
Environmental Health Perspectives|June 22, 2010
Research recommendations for selected IARC-classified agentsElizabeth M Ward, Paul A Schulte, Kurt Straif, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 10, 2025
The Pattern and Stages of Atrophy in Spinocerebellar Ataxia Type 2: Volumetrics from ENIGMA-AtaxiaJason W Robertson, Isaac Adanyeguh, Benjamin Bender, et al.
Pageof 85